全文获取类型
收费全文 | 5053篇 |
免费 | 561篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 125篇 |
妇产科学 | 92篇 |
基础医学 | 263篇 |
口腔科学 | 89篇 |
临床医学 | 426篇 |
内科学 | 630篇 |
皮肤病学 | 22篇 |
神经病学 | 337篇 |
特种医学 | 85篇 |
外科学 | 312篇 |
综合类 | 578篇 |
一般理论 | 4篇 |
预防医学 | 1650篇 |
眼科学 | 62篇 |
药学 | 425篇 |
2篇 | |
中国医学 | 433篇 |
肿瘤学 | 118篇 |
出版年
2024年 | 13篇 |
2023年 | 126篇 |
2022年 | 156篇 |
2021年 | 263篇 |
2020年 | 257篇 |
2019年 | 225篇 |
2018年 | 206篇 |
2017年 | 245篇 |
2016年 | 213篇 |
2015年 | 206篇 |
2014年 | 304篇 |
2013年 | 483篇 |
2012年 | 269篇 |
2011年 | 328篇 |
2010年 | 260篇 |
2009年 | 241篇 |
2008年 | 232篇 |
2007年 | 233篇 |
2006年 | 211篇 |
2005年 | 180篇 |
2004年 | 154篇 |
2003年 | 146篇 |
2002年 | 136篇 |
2001年 | 109篇 |
2000年 | 101篇 |
1999年 | 55篇 |
1998年 | 50篇 |
1997年 | 42篇 |
1996年 | 43篇 |
1995年 | 34篇 |
1994年 | 22篇 |
1993年 | 20篇 |
1992年 | 16篇 |
1991年 | 11篇 |
1990年 | 14篇 |
1989年 | 13篇 |
1988年 | 4篇 |
1987年 | 8篇 |
1986年 | 7篇 |
1985年 | 10篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1977年 | 5篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1973年 | 2篇 |
排序方式: 共有5673条查询结果,搜索用时 15 毫秒
1.
《Value in health》2020,23(8):1027-1033
ObjectivesIn many countries, future unrelated medical costs occurring during life-years gained are excluded from economic evaluation, and benefits of unrelated medical care are implicitly included, leading to life-extending interventions being disproportionately favored over quality of life-improving interventions. This article provides a standardized framework for the inclusion of future unrelated medical costs and demonstrates how this framework can be applied in England and Wales.MethodsData sources are combined to construct estimates of per-capita National Health Service spending by age, sex, and time to death, and a framework is developed for adjusting these estimates for costs of related diseases. Using survival curves from 3 empirical examples illustrates how our estimates for unrelated National Health Service spending can be used to include unrelated medical costs in cost-effectiveness analysis and the impact depending on age, life-years gained, and baseline costs of the target group.ResultsOur results show that including future unrelated medical costs is feasible and standardizable. Empirical examples show that this inclusion leads to an increase in the ICER of between 7% and 13%.ConclusionsThis article contributes to the methodology debate over unrelated costs and how to systematically include them in economic evaluation. Results show that it is both important and possible to include future unrelated medical costs. 相似文献
2.
3.
4.
Julia Thornton Snider Jesse Sussell Mahlet Gizaw Tebeka Alicia Gonzalez Joshua T. Cohen Peter Neumann 《Value in health》2019,22(3):332-339
Background
Payers frequently rely on budget impact model (BIM) results to help determine drug coverage policy and its effect on their bottom line. It is unclear whether BIMs typically overestimate or underestimate real-world budget impact.Objective
We examined how different modeling assumptions influenced the results of 6 BIMs from the Institute for Clinical and Economic Review (ICER).Study Design
Retrospective analysis of pharmaceutical sales data.Methods
From ICER reports issued before 2016, we collected estimates of 3 BIM outputs: aggregate therapy cost (ie, cost to treat the patient population with a particular therapy), therapy uptake, and price. We compared these against real-world estimates that we generated using drug sales data. We considered 2 classes of BIM estimates: those forecasting future uptake of new agents, which assumed “unmanaged uptake,” and those describing the contemporaneous market state (ie, estimates of current, managed uptake and budget impact for compounds already on the market).Results
Differences between ICER's estimates and our own were largest for forecasted studies. Here, ICER's uptake estimates exceeded real-world estimates by factors ranging from 7.4 (sacubitril/valsartan) to 54 (hepatitis C treatments). The “unmanaged uptake” assumption (removed from ICER's approach in 2017) yields large deviations between BIM estimates and real-world consumption. Nevertheless, in some cases, ICER's BIMs that relied on current market estimates also deviated substantially from real-world sales data.Conclusions
This study highlights challenges with forecasting budget impact. In particular, assumptions about uptake and data source selection can greatly influence the accuracy of results. 相似文献5.
The association between family affluence and smoking among 15‐year‐old adolescents in 33 European countries,Israel and Canada: the role of national wealth 下载免费PDF全文
6.
7.
目的了解上海市黄浦区社会办医疗美容机构的管理人员和医师对《医疗美容管理办法》相关内容的掌握情况,发现存在的问题并提出改善建议.方法采用现场调查与现场问卷调查相结合的方式,对在上海市黄浦区开展医疗美容科目的所有社会办医疗机构(共计38家)进行全覆盖现场调查,并对其中的管理人员41人、相关医师31人进行问卷调查.结果38家社会办医疗美容机构中,美容外科和美容皮肤科的开展率较高,分别为96.8%和97.2%,而美容牙科开展率为52.4%,美容中医科开展率最低(25.0%).管理人员关于非主诊医师可在主诊医师指导下工作的知晓率仅68.3%.关于美容外科、皮肤科、中医科、牙科主诊医师应具备的工作年限,管理人员答对率为90.2%,医师答对率为72.0%,二者有显著性差异(P<0.05).结论社会办医疗美容机构中的二级科目设置需进一步优化,以减少资源空置.应加强对医疗机构管理人员和医师的法律培训,改变经营模式,制定明确的准入与退出机制,从而减少违法违规行为的发生. 相似文献
8.
Rasaki Stephen Dauda 《The International journal of health planning and management》2019,34(1):324-337
Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) is one of the leading causes of morbidity and mortality in West Africa. Prevalence among the most productive age group in West and Central Africa stood at 1.5%, 3.4.0%, 2.5%, and 2.1% in 1990, 2000, 2010, and 2015 respectively. This study examined the effect of HIV/AIDS on economic growth in West Africa with focus on 11 countries. The augmented Solow model, rooted in the neoclassical growth theory, was used, which was operationalized using dynamic panel data modeling approach. Incidence, prevalence, number of people living with HIV/AIDS (PLWHA), and AIDS‐related deaths were used to measure HIV/AIDS. Estimations using system GMM returned statistically significant results while those of first difference and difference GMM were not. From the outcome of system GMM analysis, a percentage increase in incidence, prevalence, PLWHA, and AIDS deaths correspondingly reduced growth significantly through their effects on life expectancy by 0.15%, 0.02%, 0.004%, and 0.03%. Acquired immune deficiency syndrome deaths and PLWHA lowered economic growth through enrolment but not significantly. The import of the findings is that HIV/AIDS threatens growth through life expectancy in West Africa. Therefore, its spread in the subregion should be effectively contained while proper treatment should be provided for all infected persons. 相似文献
9.
《Value in health》2020,23(10):1340-1348
ObjectivesWe applied principles for conducting economic evaluations of factorial trials to a trial-based economic evaluation of a cluster-randomized 2 × 2 × 2 factorial trial. We assessed the cost-effectiveness of atorvastatin, omega-3 fish oil, and an action-planning leaflet, alone and in combination, from a UK National Health Service perspective.MethodsThe Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes (AFORRD) Trial randomized 800 patients with type 2 diabetes to atorvastatin, omega-3, or their respective placebos and randomized general practices to receive a leaflet-based action-planning intervention designed to improve compliance or standard care. The trial was conducted at 59 UK general practices. Sixteen-week outcomes for each trial participant were extrapolated for 70 years using the United Kingdom Prospective Diabetes Study Outcomes Model v2.01. We analyzed the trial as a 2 × 2 factorial trial (ignoring interactions between action-planning leaflet and medication), as a 2 × 2 × 2 factorial trial (considering all interactions), and ignoring all interactions.ResultsWe observed several qualitative interactions for costs and quality-adjusted life-years (QALYs) that changed treatment rankings. However, different approaches to analyzing the factorial design did not change the conclusions. There was a ≥99% chance that atorvastatin is cost-effective and omega-3 is not, at a £20 000/QALY threshold.ConclusionsAtorvastatin monotherapy was the most cost-effective combination of the 3 trial interventions at a £20 000/QALY threshold. Omega-3 fish oil was not cost-effective, while there was insufficient evidence to draw firm conclusions about action planning. Recently-developed methods for analyzing factorial trials and combining parameter and sampling uncertainty were extended to estimate cost-effectiveness acceptability curves within a 2x2x2 factorial design with model-based extrapolation. 相似文献
10.
医学插图的艺术创作 总被引:1,自引:1,他引:0
高平 《中国医学教育技术》2006,20(4):350-352
介绍了医学插图艺术创作的方法:即在依据医学科学内容的基础上,遵循美学规律,运用科学的艺术表现形式,准确、形象、生动地表达出医学科学的深刻内涵,从而实现医学科学与艺术完美结合的创作目标。 相似文献